Traumatic glaucoma
Hyphaema
Pathogenesis
A traumatic hyphaema may be associated with IOP elevation due to trabecular blockage by red blood cells. Pupillary occlusion by a blood clot may be superimposed on an angle-closure component. Secondary haemorrhage, often more severe than the primary bleed, may develop within 3–5 days of the initial injury. Patients with sickle-cell haemoglobinopathies are at increased risk of developing complications associated with traumatic hyphaema.
Risk of glaucoma
Although most traumatic hyphaemas are relatively innocuous and transient, severe and prolonged elevation of IOP may damage the optic nerve and cause blood staining of the cornea; the latter can progress very rapidly. The size of a hyphaema is a useful indicator of visual prognosis and risk of complications:
•Hyphaema involving less than half the anterior chamber (Fig. 10.60) is associated with a 4% incidence of raised IOP, a 22% incidence of complications and a final visual acuity of >6/18 in 78% of eyes.
•Hyphaema involving over half the anterior chamber is associated with an 85% incidence of raised IOP, 78% incidence of complications and a final visual acuity of >6/18 in only 28% of eyes.
Fig. 10.60 Small hyphaema with a low risk of glaucoma
Treatment
1General
•A coagulation abnormality, particularly a haemoglobinopathy, should be excluded.
•Any current anticoagulant medication should be discontinued after liaison with a general physician to assess the risk; NSAIDs should not be used for analgesia.
•Hospital admission may be required for large hyphaemas.
•Strict bed rest is probably unnecessary, but substantially limiting activity is prudent, and the patient should remain in a sitting or semi-upright posture, including during sleep.
2Medical
•A beta-blocker and/or a topical or systemic CAI is administered (not in sickle haemoglobinopathies if possible) depending on the IOP. Miotics should be avoided as they may increase pupillary block and disrupt the blood-aqueous barrier, and prostaglandins as they may promote inflammation. Alpha-agonists may be useful, but are avoided in small children and sickling disorders.
•Occasionally a hyperosmotic agent is needed.
•Topical steroids should be used since they reduce inflammation and possibly the risk of secondary haemorrhage.
•Mydriatics are controversial. Atropine is recommended by some authorities to achieve constant mydriasis rather than a mobile pupil, in order to minimize the chances of secondary haemorrhage.
•Systemic antifibrinolysis (aminocaproic acid or tranexamic acid) is rarely given now; topical aminocaproic acid shows